Cellectar Biosciences Reports Financial Results and Advances Iopofosine I-131 Toward Conditional Marketing Authorization Submission in Europe for Waldenström Macroglobulinemia Treatment

Cellectar Biosciences reported financial results for the year ended 2025 and provided updates on its pipeline. The company plans to submit Conditional Marketing Authorization for iopofosine I 131 in Q3 2026 for potential 2027 EU commercialization as a treatment for Waldenström Macroglobulinemia. A Phase 1b dose finding study for CLR 125 in Triple Negative Breast Cancer has been initiated, with early data expected by mid-year 2026. The company expects important clinical readouts, continued regulatory progress, and expansion of its next-generation Phospholipid Drug Conjugate programs in 2026.